WRAP Retail Offer for up to £150,000

London, UK - ValiRx Plc (AIM: VAL), an innovative life sciences company focusing on early-stage cancer therapeutics and women's health, with a pipeline of assets including CLX001 and VAL201, is pleased to announce a retail offer via the Winterflood Retail Access Platform ("WRAP") to raise up to £150,000 (the "WRAP Retail Offer") through the issue of new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"). Under the WRAP Retail Offer up to 75,000,000 new Ordinary Shares (the "WRAP Retail Offer Shares") will be made available at an issue price of 0.2 pence per share ("Issue Price"). As part of the WRAP Retail Offer, the Company has agreed that one warrant for every one WRAP Retail Offer Share will be granted (for no additional subscription cost), with each warrant entitling the holder to acquire one new Ordinary Share at a price of 0.28 pence, subject to obtaining shareholder authority at its upcoming annual general meeting in June 2026, as set out in the Company's announcement of 15 May 2026 (the "Fundraising Warrants"). The Fundraising Warrants are exercisable at any time until the third anniversary of the date of grant.

Mark Eccleston, Chief Executive Officer of the Company, has indicated his intention to subscribe for 25,000,000 new Ordinary Shares pursuant to the WRAP Retail Offer.

In addition to the WRAP Retail Offer and as announced at 7.00 a.m. on 15 May 2026, the Company has raised £1,005,000 through the Placing and Subscription (together the "Fundraise") of new Ordinary Shares at the Issue Price. The Issue Price represents a discount of approximately 17 per cent. to the mid-market closing price of 0.241 pence per Ordinary Share on 14 May 2026. The issue price of the WRAP Retail Offer Shares is equal to the Issue Price.

The grant of the Fundraising Warrants is subject to shareholder approval of sufficient allotment authorities to be sought at the Company's next annual general meeting. Should the relevant shareholder approval not be obtained, participants in the WRAP Retail Offer will receive only the WRAP Retail Offer Shares subscribed for, and not the related Fundraising Warrants.

A separate announcement has been made regarding the Placing and Subscription and its terms and sets out its use of proceeds. The net proceeds of the WRAP Retail Offer will be utilised in the same way as the net proceeds of the Placing and Subscription.

The issue of the WRAP Retail Offer Shares will also be conditional upon the WRAP Retail Offer Shares being admitted to trading on AIM ("Admission"). It is anticipated that Admission will become effective and that dealings in the WRAP Retail Offer Shares will commence at 8:00 a.m. on 1 June 2026.

The Company has also agreed to grant Winterflood up to 3,750,000 Broker Warrants. . The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of the date of grant. The Broker Warrants will be granted to Winterflood, conditional inter alia on shareholder approval of sufficient allotment authorities to be sought at the Company's next annual general meeting.

WRAP Retail Offer

The Company values its retail shareholder base and believes that it is appropriate to provide both new and existing shareholders in the United Kingdom the opportunity to participate in the WRAP Retail Offer.

Therefore, the Company is making the WRAP Retail Offer available to eligible investors in the United Kingdom, being new or existing shareholders of ValiRx, following release of this announcement and through certain financial intermediaries.

The WRAP Retail Offer is expected to close at 4:30 p.m. on 20 May 2026. Eligible retail investors should note that financial intermediaries may have earlier closing times. The result of the WRAP Retail Offer is expected to be announced by the Company on or around 21 May 2026.

Retail brokers wishing to participate in the WRAP Retail Offer on behalf of eligible investors, should contact wrap@winterflood.com.

There is a minimum subscription of £100 per investor under the WRAP Retail Offer. The terms and conditions on which investors subscribe will be provided by the relevant financial intermediaries including relevant commission or fee charges.

Investors should note that once an application for WRAP Retail Offer Shares has been made and accepted via an intermediary, it cannot be withdrawn.

The WRAP Retail Offer is not being made into any jurisdiction other than the United Kingdom.

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the announcement on 15 May 2026.

UK Product Governance Requirements